Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic and Alnylam announce results of Huntington’s trial

Medtronic and Alnylam announce results of Huntington’s trial

18th September 2009

Medtronic and Alnylam Pharmaceuticals have revealed new pre-clinical research data from a study into the treatment of Huntington’s Disease.

Presented at the 2009 World Congress on Huntington’s Disease in Vancouver this week, the findings support the two companies’ development of a drug-device combination for Huntington’s treatment.

The research demonstrates that an RNAi therapeutic targeting huntingtin, the gene responsible for the condition, can achieve broad distribution in the central nervous system following direct administration.

“We are very pleased with these promising results in our Huntington’s disease program, as it continues to represent an exciting opportunity to combine innovative medicines with our state-of-the-art drug device delivery technology,” commented Gregory Stewart, director of CNS Drug Therapy R&D at Medtronic.

“The convergence of Alnylam and Medtronic technologies could provide a novel treatment strategy for this devastating neurodegenerative disease,” he added.

An inflatable pump device developed by Medtronic is used to deliver the treatment from Alnylam Pharmaceuticals into the central nervous system.

Earlier this week, a study sponsored by Medtronic revealed that heart failure patients with ejection fractions above 35 per cent may receive comparable benefits from cardiac resynchronisation therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.